Recurrent Neuroblastoma (DBCOND0028756)

Identifiers

Synonyms

Neuroblastoma Recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06541262	Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors	Irinotecan Silmitasertib Temozolomide Vincristine	treatment	1 / 2	recruiting
NCT05754684	Quadruple Immunotherapy for Neuroblastoma	Aldesleukin Dinutuximab Natural Killer Cell Naxitamab Sargramostim Spironolactone	treatment	2	recruiting
NCT06465199	Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas	Eflornithine	treatment	1 / 2	not_yet_recruiting
NCT06540963	Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma	Naxitamab Tipifarnib	treatment	2	not_yet_recruiting
NCT03242603	Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells	Natural Killer Cell	treatment	1 / 2	unknown_status
NCT02139397	Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma	Bortezomib Bortezomib D-mannitol Eflornithine	treatment	1 / 2	completed
NCT04903899	177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma	Lutetium Lu 177 dotatate	treatment	2	recruiting
NCT01467986	Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma	Dasatinib Irinotecan Sirolimus Temozolomide	treatment	2	completed
NCT04560166	Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma	Irinotecan Naxitamab Temozolomide	treatment	2	terminated
NCT03373097	Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors	No drug interventions	treatment	1 / 2	recruiting
NCT02258815	CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma	Dinutuximab	treatment	2	completed
NCT04239092	9-ING-41 in Pediatric Patients With Refractory Malignancies.	Cyclophosphamide Elraglusib Irinotecan Temozolomide Topotecan	treatment	1	recruiting
NCT03210714	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)	Erdafitinib	treatment	2	active_not_recruiting
NCT03213678	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	LY-3023414	treatment	2	active_not_recruiting
NCT03213704	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)	Larotrectinib Sulfate ion	treatment	2	active_not_recruiting
NCT04320888	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	Selpercatinib	treatment	2	active_not_recruiting
NCT04539366	Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT00026312	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	Aldesleukin Dinutuximab Isotretinoin Sargramostim	treatment	3	active_not_recruiting
NCT01711554	Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	Dinutuximab Isotretinoin Lenalidomide	treatment	1	active_not_recruiting
NCT03155620	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	Ensartinib Erdafitinib Hydrogen LY-3023414 Larotrectinib Menthol Olaparib Palbociclib Selpercatinib Selumetinib Sulfate ion Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-396	screening	2	recruiting
NCT03213652	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)	Ensartinib X-396	treatment	2	recruiting
NCT03526250	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)	Palbociclib	treatment	2	active_not_recruiting
NCT03698994	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Ulixertinib	treatment	2	active_not_recruiting
NCT04195555	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)	Ivosidenib	treatment	2	active_not_recruiting
NCT04284774	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial	Tipifarnib	treatment	2	active_not_recruiting
NCT00093821	Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors	Tanespimycin	treatment	1	completed
NCT04901702	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma	Irinotecan Talazoparib Temozolomide	treatment	1 / 2	active_not_recruiting
NCT04530487	Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults	Antithymocyte immunoglobulin (rabbit) Beta-D-Glucose Cyclosporine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus Thiotepa Tromethamine	treatment	2	terminated
NCT02075177	Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma	Fenretinide Ketoconazole	Not Available	Not Available	no_longer_available
NCT00054405	Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma	Aldesleukin Edodekin alfa Natural Killer Cell	treatment	1	terminated
NCT01606878	Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Crizotinib Cyclophosphamide Dexrazoxane Doxorubicin Sulfate ion Topotecan Tyrosine Vincristine	treatment	1	completed
NCT00004078	Irinotecan in Treating Children With Refractory Solid Tumors	Irinotecan	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT02163356	Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma	Fenretinide Ketoconazole Vincristine	treatment	1	terminated
NCT01334515	Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma	Isotretinoin Lorukafusp alfa Sargramostim	treatment	2	completed
NCT02095132	Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors	Adavosertib Camptothecin Irinotecan	treatment	1 / 2	completed
NCT00939770	Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	Crizotinib Tyrosine	treatment	1 / 2	completed
NCT03794349	Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma	Camptothecin Dinutuximab Eflornithine Irinotecan Sargramostim Temozolomide	treatment	2	active_not_recruiting
NCT01358617	Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma	No drug interventions	Not Available	Not Available	completed
NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas	Ipilimumab Nivolumab	treatment	1 / 2	completed
NCT00028522	R(+)XK469 in Treating Patients With Advanced Neuroblastoma	No drug interventions	treatment	1	completed
NCT04500548	Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	Ipilimumab Nivolumab	treatment	1	withdrawn
NCT03057626	Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma	No drug interventions	Not Available	Not Available	active_not_recruiting
NCT00053326	Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma	Fenretinide	treatment	2	completed
NCT03213665	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)	Tazemetostat	treatment	2	active_not_recruiting
NCT01767194	Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma	Camptothecin Dinutuximab Irinotecan Menthol Sargramostim Sirolimus Temozolomide Temsirolimus	treatment	2	completed
NCT00831844	Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors	Cixutumumab	treatment	2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT03209869	Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2	Lorukafusp alfa Natural Killer Cell	treatment	1	withdrawn
NCT00217412	Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia	Isotretinoin Vorinostat	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00331643	Ixabepilone in Treating Young Patients With Refractory Solid Tumors	Ixabepilone Patupilone	treatment	2	completed
NCT00077454	Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors	Erlotinib Temozolomide	treatment	1	completed
NCT02452554	Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma	Lorvotuzumab mertansine	treatment	2	completed
NCT01208454	Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma	Isotretinoin Vorinostat	treatment	1	completed
NCT00638898	Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor	Busulfan Filgrastim Melphalan Topotecan	treatment	1	active_not_recruiting
NCT04751383	Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma	Dinutuximab Magrolimab	treatment	1	active_not_recruiting
NCT02173093	Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma	Aldesleukin Sargramostim	treatment	1 / 2	unknown_status
NCT00309907	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant	Etanercept Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00436852	ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment	ABT-751	treatment	2	completed
NCT00101270	Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas	Irinotecan Oxaliplatin	treatment	1	completed
NCT00075634	Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma	2'-Deoxycytidine Cyclophosphamide Decitabine Doxorubicin Filgrastim Pegfilgrastim	treatment	1	completed
NCT01154816	Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia	Alisertib	treatment	2	completed
NCT00436696	Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions	No drug interventions	Not Available	Not Available	completed
NCT03220035	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	Vemurafenib	treatment	2	active_not_recruiting
NCT02011126	Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors	Grn163l Imetelstat	treatment	2	withdrawn
NCT00091182	Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment	Oxaliplatin	treatment	2	completed
NCT00005576	Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma	Aldesleukin Dinutuximab Isotretinoin Sargramostim	treatment	1	completed
NCT00898391	Study of DNA in Blood Samples From Patients With Neuroblastoma	No drug interventions	Not Available	Not Available	completed
NCT03213691	Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	Hydrogen Selumetinib Sulfate ion	treatment	2	active_not_recruiting
NCT00030667	Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood	Imatinib	treatment	2	completed
NCT00567567	Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma	Beta-D-Glucose Carboplatin Chloride ion Cisplatin Cyclophosphamide Doxorubicin Etoposide Filgrastim Isotretinoin Mechlorethamine Platinum Thiotepa Topotecan Tromethamine Vincristine	treatment	3	completed
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT03233204	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)	Olaparib	treatment	2	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT00012181	Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas	Alvocidib	treatment	1	completed
NCT02641314	Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma	Celecoxib Cyclophosphamide Etoposide Propranolol	treatment	2	completed
NCT00053950	Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma	Filgrastim Pyrazoloacridine	treatment	1	terminated